- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Evolving strategies for addressing CAR T-cell toxicities ; volume:44 ; number:1 ; day:15 ; month:12 ; year:2024 ; pages:1-29 ; date:3.2025
Cancer and metastasis reviews ; 44, Heft 1 (15.12.2024), 1-29, 3.2025
- Urheber
-
Rankin, Alexander W.
Duncan, Brynn B.
Allen, Cecily
Silbert, Sara K.
Shah, Nirali N.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10555-024-10227-1
- URN
-
urn:nbn:de:101:1-2502262121071.441567760120
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Rankin, Alexander W.
- Duncan, Brynn B.
- Allen, Cecily
- Silbert, Sara K.
- Shah, Nirali N.
- SpringerLink (Online service)
Ähnliche Objekte (12)
New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies
CAR T-Cell therapy
Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy
Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy
The CAR T‐Cell Mechanoimmunology at a Glance
Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?
The NIDA clinical trials network: evolving, expanding, and addressing the opioid epidemic
CAR T-cell therapy in diffuse large B-cell lymphoma
Hepatitis B virus reactivation associated with CAR T-cell therapy
Advances in CAR-T-cell therapy in T-cell malignancies
Fueling CARs: metabolic strategies to enhance CAR T-cell therapy
New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies
CAR T-Cell therapy
Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy
Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy
The CAR T‐Cell Mechanoimmunology at a Glance
Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?
The NIDA clinical trials network: evolving, expanding, and addressing the opioid epidemic
CAR T-cell therapy in diffuse large B-cell lymphoma
Hepatitis B virus reactivation associated with CAR T-cell therapy
Advances in CAR-T-cell therapy in T-cell malignancies
Fueling CARs: metabolic strategies to enhance CAR T-cell therapy
New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies
CAR T-Cell therapy
Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy
Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy
The CAR T‐Cell Mechanoimmunology at a Glance
Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?
The NIDA clinical trials network: evolving, expanding, and addressing the opioid epidemic
CAR T-cell therapy in diffuse large B-cell lymphoma
Hepatitis B virus reactivation associated with CAR T-cell therapy
Advances in CAR-T-cell therapy in T-cell malignancies